trending Market Intelligence /marketintelligence/en/news-insights/trending/qswoNJPX_9zs7KAr4qAyZg2 content esgSubNav
In This List

FibroGen files for US approval of anemia drug Evrenzo

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation

Blog

Using Credit Analytics to Avoid Mispricing Insurance Premiums

Blog

Post-Webinar Q&A: Integrating Climate Risks into Credit Risk Portfolios


FibroGen files for US approval of anemia drug Evrenzo

FibroGen Inc. filed an application seeking U.S. approval of its anemia drug Evrenzo, or roxadustat, for patients with chronic kidney disease.

Evrenzo is already approved in Japan for dialysis-dependent patients and in China for both non-dialysis-dependent and dialysis-dependent patients.

The San Francisco-based biotechnology company's new drug application with the U.S. Food and Drug Administration is based on results from 15 phase 3 trials — including Olympus, Andes, Alps, Himalayas, Sierras and Rockies — that evaluated Evrenzo's efficacy and safety in about 10,000 patients globally.

Low levels of hemoglobin, an oxygen-carrying protein in red blood cells, and insufficient red blood cells can lead to anemia, a potentially life-threatening condition common in patients with chronic kidney disease.

FibroGen is collaborating with Britain's AstraZeneca PLC to commercialize roxadustat for the treatment of anemia in the U.S. and certain other geographies.